A Potent Specific Pure Antiestrogen with Clinical Potential

Cancer Research

Volumn 51, Issue 15, 1991, Pages 3867-3873

  Wakeling, Alan E ^a   Dukes, Michael ^a   Bowler, Jean ^a  

^a AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; 7ALPHA [9 (4,4,5,5 PENTAFLUOROPENTYLSULFINYL)NONYL]ESTRA 1,3,5(10) TRIENE 3,17BETA DIOL; ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; GROWTH INHIBITION; HORMONE INHIBITION; HORMONE RECEPTOR INTERACTION; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; TUMOR GROWTH; UTERUS;

ANIMAL; BREAST NEOPLASMS; COMPARATIVE STUDY; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; MACACA NEMESTRINA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIECTOMY; RATS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED; UTERUS;

EID: 0026395885     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Litherland, S., and Jackson, I. M. Antioestrogens in the management of hormone-dependent breast cancer. Cancer Treat. Rev., 15: 183–194, 1988.
2. Early Breast Cancer Triallists’ Collaborative Group. Treatment of Early Breast Cancer, Vol. 1. Oxford, United Kingdom: Oxford University Press, 1990.
3. Nicholson, R. I. Antioestrogens and breast cancer therapy. In: B. J. A. Furr and A. E. Wakeling (eds.), Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, pp. 60–86. Eastbourne, England: Bailliere Tindall, 1987.
4. Jordan, V. C., and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev., 11: 578–610, 1990.
5. Furr, B. J. A., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25: 127–205, 1984.
6. May, F. E. B., and Westley, B. R. Effects of tamoxifen and 4′-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells. J. Biol. Chem., 262: 15894–15899, 1987.
7. Wakeling, A. E. Novel pure antiestrogens: mode of action and therapeutic prospects. Ann. NY Acad. Sci., 595: 348–356, 1990.
8. Wakeling, A. E. Therapeutic potential of pure antiestrogens in the treatment of breast cancer. J. Steroid Biochem., 37: 771–775, 1990.
9. Wakeling, A. E., and Bowler, J. Steroidal pure antiestrogens. J. Endocrinol., 112.R7-R10, 1987.
10. Bowler, J., Lilley, T. J., Pittam, J. D., and Wakeling, A. E. Novel steroidal pure antiestrogens. Steroids, 54: 71–99, 1989.
11. Wakeling, A. E., and Bowler, J. Biology and mode of action of pure antiestrogens. J. Steroid Biochem., 30: 141–147, 1988.
12. Wakeling, A. E. Steroidal pure antiestrogens. In: M. Lippman and R. Dickson (eds.), Regulatory Mechanisms in Breast Cancer, pp. 239–257. Boston: Kluwer Academic Publishers, 1990.
13. Wakeling, A. E., and Slater, S. R. Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat. Rep., 64: 741–744, 1980.
14. Wakeling, A. E. Anti-hormones and other steroid analogues. In: B. Green and R. E. Leake (eds.), Steroid Hormones: A Practical Approach, pp. 219– 236. Oxford, United Kingdom: IRL Press, 1987.
15. Wakeling, A. E., and Bowler, J. Novel antioestrogens without partial agonist activity. J. Steroid Biochem., 31:645–653, 1988.
16. Wakeling, A. E., Newboult, E., and Peters, S. E. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J. Mol. Endocrinol., 2:225–234, 1989.
17. Wakeling, A. E., O'Connor, K. M., and Newboult, E. Comparison of the biological effects of tamoxifen and a new antiestrogen (LY 117018) on the immature rat uterus. J. Endocrinol., 99: 447–453, 1983.
18. Niswender, G. D., Reichert, L. E., Jr., Midgley, A. R., and Nalbandov, A. V. Radioimmunoassay for bovine and ovine luteinizing hormone. Endocrinology, 84: 1166–1173, 1969.
19. Nicholson, R. I., Gotting, K. E., Gee, J., and Walker, K. J. Actions of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention. J. Steroid Biochem., 30: 95–103, 1988.
20. Galman, M. S., Sundstrom, S. A., and Lyttle, C. R. Antagonism of estrogen and antiestrogen-induced uterine complement component C3 expression by ICI 164,384. J. Steroid Biochem., 36: 281–286, 1990.
21. Gottardis, M. M., Jiang, S-Y., Jeng, M-H., and Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49:4090–4093, 1989.
22. Gottardis, M. M., Ricchio, M. E., Satyaswaroop, P. G., and Jordan, V. C. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCalOl) in athymic mice. Cancer Res., 50: 3189–3192, 1990.
23. Weaver, C. A., Springer, P. A., and Katzenellenbogen, B. S. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. J. Mol. Endocrinol., 2:936–945, 1988.
24. Berry, M., Nunez, A-M., and Chambon, P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc. Natl. Acad. Sci. USA, 86: 1218–1222, 1989.
25. Berry, M., Metzger, D., and Chambon, P. Role of the two activating domains of the estrogen receptor in the cell-type and promotor-context dependent agonistic activity of the antiestrogen 4-hydroxytamoxifen. EMBO J., 9: 2811–2818, 1990.
26. Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., and Parker, M. G. Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA, 87:6883–6887, 1990.
27. Wilson, A. P. M., Weatherill, P. J., Nicholson, R. I., Davies, P., and Wakeling, A. E. A comparative study of the interaction of oestradiol and the steroidal antiestrogen, ICI 164,384, with the molybdate-stabilized oestrogen receptor. J. Steroid Biochem., 35:421–428, 1990.
28. Musgrove, E. A., Wakeling, A. E., and Sutherland, R. L. Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res., 49: 2398–2404, 1989.
29. Thomson, E. W., Katz, D., Shima, T. B., Wakeling, A. E., Lippman, M. E., and Dickson, R. B. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res., 49: 6929–6934, 1989.
30. Wakeling, A. E. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J. Steroid Biochem., 34:183–188, 1989.
31. Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J., and Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res., 47:4355–4360, 1987.
32. Stewart, A. J., Johnson, M. D., May, F. E. B., and Westley, B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem., 265: 21172–21178, 1990.
33. Wakeling, A. E. Chemical structure and pharmacology of anti-oestrogens. History, current trends and future prospects. In: F. Pannuti (ed.), Antioestrogens in Oncology. Current Clinical Practice Series No. 31, pp. 43–53. Amsterdam: Excerpta Medica, 1985.
34. Osborne, C. K., Hobbs, K., and Clark, G. M. Effect of estrogens and antiestrogens on growth of human breast cancer in athymic nude mice. Cancer Res., 45: 584–590, 1985.
35. Brunner, N., Bronzert, D., Vindelov, L. L., Rygaard, K., Spang-Thomsen, M., and Lippman, M. E. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res., 49:1515–1520, 1989.
36. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res., 51:162–166, 1991.
37. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183–5187, 1988.
38. Howell, A., Dodwell, D. J., Laidlaw, I., Anderson, H., and Anderson, E. Tamoxifen as an agonist for metastatic breast cancer. In: A. Goldhirsch (ed.), Endocrine Therapy of Breast Cancer IV, pp. 49–58. Berlin: Springer-Verlag, 1990.
39. Reddel, R. R., and Sutherland, R. L. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur. J. Cancer Clin. Oncol., 20: 1419–1424, 1984.
40. Gusberg, S. B. Tamoxifen for breast cancer: associated endometrial cancer. Cancer (Phila.), 65: 1463–1464, 1990.
41. Hirohashi, S., Shimosato, Y., Kameya, T., Nagai, K., and Tsunematsu, R. Hormone dependency of a serially transplantable human breast cancer (Br 10) in nude mice. Cancer Res., 37: 3184–3189, 1977.
42. Spang-Thomsen, M., Rygaard, K., Hansen, L., Halvorsen, A-C, Vindeløv, L. L., and Brünner, N. Growth kinetics of four human breast carcinomas grown in nude mice. Breast Cancer Res. Treat., 14: 235–243, 1989.
43. Kubota, T., Hirohashi, S., Shimosato, Y., Ishibiki, K., and Abe, O. Experimental chemotherapy and hormone therapy on human breast carcinoma (Br 10) serially transplanted to nude mice. Cancer Chemother. (Jpn.), 7:257– 264, 1980.
44. Nicholson, R. I., Walker, K. J., Bouzubar, N., Wills, R. J., Gee, J. M. W., Rushmere, N. K., and Davies, P. Estrogen deprivation in breast cancer. Clinical, experimental and biological aspects. Ann. NY Acad. Sci., 595:316– 327, 1990.